ClinicalTrials.gg
CompletedNCT02177357Updated Jun 27, 2014

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

A Phase 3 interventional study of Pramipexole and Placebo in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
18th of 26
150 · median 224
Started
1998
with 1 other
Phase 3
11 of 26
none open now
Registered
21st of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 18th largest by enrollment, is one of 2 that started in 1998, is one of 11 in phase 3, and was the 21st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objectives of this study were to evaluate the efficacy, safety, and tolerability of pramipexole, as single-agent therapy or in combination with levodopa, in patients with Parkinson disease living in Hong Kong and Taiwan.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females at least 30 years of age with a diagnosis of symptomatic, idiopathic Parkinson disease, stage 1-4 on the Modified Hoehn and Yahr Scale
  • Females either surgically sterile or at least 2 years , or using a reliable method of for at least 2 months prior to study entry
  • Females of with a negative pregnancy test at the screening visit and not nursing
  • Patients with at least 3 of the 4 cardinal signs of Parkinson disease (i.e., rigidity, bradykinesia, resting tremor, postural instability) and without any other known or Suspected cause for their Parkinsonism
  • Patients on levodopa therapy who show a good response to levodopa and be on a stable dosage of levodopa for least 1 month prior to study entry
  • Patients able to take oral medication
  • Patients must give voluntary written consent for study participation and must sign a Patient Form at the screening visit, prior to initiation of any study-related procedures

Exclusion criteria

Exclusion Criteria:

  • Atypical parkinsonian syndromes secondary to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy, multiple-system atrophy)
  • Dementia that could impair compliance with medication and/or preclude giving (i.e., Mini-Mental Status Examination score ≤22)
  • History of psychosis
  • History of active epilepsy (e.g., occurrence of a seizure) within 1 year prior to screening
  • Second or third degree atrioventricular block or sick sinus syndrome, resting heart rate below 50 beats per minute, congestive heart failure ( functional Class III or IV), myocardial infarction within 6 months of randomization, or other heart conditions (e.g., coronary artery disease) that might negatively affect the possibility of the patient completing the study
  • Clinically significant liver disease that may prevent the patient from completing the study and/or elevation in total , alkaline phosphatase, lactate dehydrogenase (LDH), serum glutamate pyruvate transaminase (), or serum glutamate oxaloacetate transaminase (SGOT) of >1.5 times the values
  • Clinically significant renal disease that may prevent the patient from completing the study and/or elevation in serum creatinine of >1.5 times the upper limit of the normal values
  • Presence of active neoplastic disease
  • Surgery within 6 months of the baseline/randomization visit which, in the opinion of the investigator, might negatively impact the patient's participation in the study, or any history of stereotaxic brain surgery (e.g., thalamotomy, pallidotomy, or any other deep brain stimulation for reduction of parkinsonian symptoms)
  • Supine systolic blood pressure less than 100 mm Hg or evidence of a ≥20-mm Hg decline in systolic blood pressure at 2 minutes after standing, compared with the previous supine systolic blood pressure obtained after 5 minutes of quiet rest, if the decline in blood pressure upon standing is associated with symptoms (i.e., symptomatic orthostatic hypotension)
  • Use of dopamine agonist medications (e.g., bromocriptine, pergolide) in the 2 months prior to study entry (allowed medications: selegiline, anticholinergics, and amantadine therapy at a stable dosage for 60 days prior to study entry and remaining stable throughout the study)
  • Use of neuroleptics, alpha-methyldopa, or flunarizine within the past 6 months
  • Use of any of the following drugs within 3 months of study entry: methylphenidate, cinnarizine, reserpine, amphetamine, and monoamine oxidase-A inhibitors (e.g., pargyline, phenelzine, or tranylcypromine)
  • Use of pramipexole within the past 3 months or a history of adverse reaction or allergy to pramipexole
  • Unstable dosage of centrally active therapies (e.g., hypnotics, antidepressants, anxiolytics) within the past 60 days
  • Electroconvulsive therapy within 90 days of the baseline/randomization visit
  • Participation in other drug studies or receipt of other investigational drugs within 30 days prior to baseline/randomization. Investigational drugs for Parkinson disease must have been discontinued for 90 days prior to baseline/randomization. Additionally, patients previously randomized into this study and who then discontinued study participation are not to be re-entered into the study
  • Positive screen (assessed at the screening visit)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Pramipexole - escalation dose

    Drug: Pramipexole

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the sum of the UPDRS (Unified Parkinson Disease Rating Scale) Parts II and III total scores.

    Time frame: up to 15 weeks

  2. Number of patients with clinically significant changes in vital signs

    Time frame: up to 15 weeks

  3. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 15 weeks

  4. Number of patients with abnormal changes in 12-lead ECG (electrocardiogram)

    Time frame: up to 15 weeks

  5. Number of patients with adverse events

    Time frame: up to 15 weeks

Secondary outcomes

  1. Change from baseline in the individual UPDRS Part II and Part III total scores

    Time frame: up to 15 weeks

  2. Change from baseline the individual items in the UPDRS Part II and Part III

    Time frame: up to 15 weeks

  3. Change from baseline in the Modified Hoehn and Yahr Scale

    Time frame: up to 15 weeks

  4. Change from baseline in the number of "off" hours in those patients who had been on levodopa therapy

    Time frame: up to 15 weeks

  5. Change from baseline in the Mini-Mental Status Examination

    Time frame: up to 15 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998 and a primary completion of Jan 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 27, 2014
Start
Nov 1998
Primary completionActual
Jan 2000
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02177357
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Nov 1998
Primary completion
Jan 2000
Last update
Jun 27, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion